A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia.

Trial Profile

A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Elacytarabine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Aqualis
  • Most Recent Events

    • 10 Dec 2012 Final results have been presented at the 2012 Annual Meeting of the American Society of Hematology (ASH) according to a Clavis Pharma media release. Results were also summarised in the media release.
    • 13 Nov 2012 Status changed from active, no longer recruiting to completed, according to a Clavis Pharma media release.
    • 13 Nov 2012 Final results are due to be reported in December 2012 at the American Society of Haematology meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top